Comparative Pharmacology
Head-to-head clinical analysis: IOPAMIDOL 250 IN PLASTIC CONTAINER versus RENOVUE 65.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOPAMIDOL 250 IN PLASTIC CONTAINER versus RENOVUE 65.
IOPAMIDOL-250 IN PLASTIC CONTAINER vs RENOVUE-65
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated radiographic contrast medium that attenuates X-rays and provides radiopacity in vascular and body cavities. It does not undergo significant pharmacological activity.
Iothalamate meglumine is an ionic, high-osmolality iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast. It acts by increasing the radiopacity of blood vessels and organs during imaging.
250 mg iodine/mL; 1.5 mL/kg (up to 100 mL) IV bolus or infusion for CT imaging.
Intravenous injection, 10 mL (6.48 g iobitridol) as a single dose. Repeat dosing: up to 3 additional doses within 30 minutes, maximum 40 mL per procedure.
None Documented
None Documented
Terminal elimination half-life: 2 hours (normal renal function); prolonged in renal impairment (up to 30+ hours in severe impairment), dictating contrast dosing intervals
Terminal elimination half-life: 2.0 hours in patients with normal renal function; prolonged to >24 hours in severe renal impairment (CrCl <10 mL/min).
Renal: 95% unchanged via glomerular filtration; biliary/fecal: <5%
Renal: 100% as unchanged drug; no biliary or fecal elimination.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent